SCHEMBL6474945

SCHEMBL6474945

O=S(=O)(Nc1cccc(CCOCc2cc(-c3ccc(F)cc3)ccc2Cl)c1)C(F)(F)F

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM1A O60341 1/20 0.39
CYP3A4 P08684 3/20 0.38
CYP2D6 P10635 3/20 0.38
SLC6A2 P23975 3/20 0.38
SLC6A4 P31645 3/20 0.38
SLC6A3 Q01959 3/20 0.38
KCNH2 Q12809 1/20 0.37
CA2 P00918 2/20 0.37
CYSLTR2 Q9NS75 3/20 0.37
CYSLTR1 Q9Y271 3/20 0.37
MGLL Q99685 1/20 0.36
PPARA Q07869 2/20 0.34
PPARG P37231 1/20 0.34
PRMT6 Q96LA8 1/20 0.34
PTGS1 P23219 1/20 0.33
PTGS2 P35354 1/20 0.33
AGXT P21549 1/20 0.33
TRPV1 Q8NER1 1/20 0.33
CA1 P00915 1/20 0.33
KIF11 P52732 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6481112 0.88 KDM1A (0.41) KDM1ACA2CYSLTR2CYSLTR1MGLL
SCHEMBL6479703 0.87 KDM1A (0.45) KDM1ACA2CYSLTR2CYSLTR1MGLL
SCHEMBL6479679 0.87 KDM1A (0.42) KDM1ACA2CYSLTR2CYSLTR1MGLL
SCHEMBL6474331 0.87 ERAP1 (0.38) KDM1ACA2CYSLTR2CYSLTR1MGLL
SCHEMBL6475686 0.85 PPARA (0.41) KDM1ACYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL6474008 0.85 CYP3A4 (0.45) KDM1ACYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL6480341 0.82 PPARA (0.39) KDM1ACYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL6483863 0.82 PPARA (0.47) KDM1ACYP3A4CYP2D6SLC6A2SLC6A4
SCHEMBL6482194 0.81 KDM1A (0.43) KDM1ACA2CYSLTR2CYSLTR1MGLL
SCHEMBL6482230 0.81 KIF11 (0.44) KDM1ACA2CYSLTR2CYSLTR1MGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6930131-B2 Aryl substituted 3-ethoxy phenyl trifluoromethane sulfonamides for the treatment of non-insulin dependent diabetes mellitus (NIDDM) WYETH (US) 2005-08-16 US disclosed
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus WYETH (US) 2003-10-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030203941-A1 Substituted phenyl compounds for the treatment of non-insulin dependent diabetes mellitus GPR119, INSR, SLC5A1 KDM1A 1124/4885CYP3A4 344/4885CYP2D6 688/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.